NCT03771157 · OUTCOME

Number of Participants With Cellular Response to Vaccination 2 Years After the Second Vaccine Administration

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors · Source last updated 2024-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 2 years following second vaccination, approximately 26 months from day 1

What was measured

Cellular response, as determined by measuring VZgE-specific T-cell responses in blood, 2 years after the second vaccine administration.

Groups in this outcome

Shingrix Vaccine

On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose. Antibody and cellular response to vaccination will be assessed at 24 months after the second dose.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Shingrix Vaccine	31

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Shingrix Vaccine	17	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
17

denoms

counts
group Id
OG000
value
31
units
Participants

description

Cellular response, as determined by measuring VZgE-specific T-cell responses in blood, 2 years after the second vaccine administration.

groups

description
On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose. Antibody and cellular response to vaccination will be assessed at 24 months after the second dose.
id
OG000
title
Shingrix Vaccine

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

2 years following second vaccination, approximately 26 months from day 1

title

Number of Participants With Cellular Response to Vaccination 2 Years After the Second Vaccine Administration

type

OTHER_PRE_SPECIFIED

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice